The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Fate Therapeutics Inc shares valued at $9,573 were sold by TAHL CINDY on Aug 04 ’25. At $1.06 per share, TAHL CINDY sold 9,037 shares. The insider’s holdings dropped to 397,670 shares worth approximately $0.43 million following the completion of this transaction.
Also, Valamehr Bahram sold 14,466 shares, netting a total of over 15,396 in proceeds. Following the sale of shares at $1.06 each, the insider now holds 334,898 shares.
Before that, TAHL CINDY had added 9,037 shares to its account. In a trade valued at $9,573, the Officer bought Fate Therapeutics Inc shares for $1.06 each.
As published in a research note from BofA Securities on November 18, 2024, Fate Therapeutics Inc [FATE] has been rated up from an Underperform to a Neutral. Analysts at Piper Sandler upgraded the stock from ‘”a Neutral”‘ to ‘”an Overweight”‘ outlook in a report released in mid June. Earlier on January 24, 2023, H.C. Wainwright downgraded its rating. Their new recommendation was “a Neutral” for FATE stock which previously was a “a Buy”.
Analyzing FATE Stock Performance
On last trading session, Fate Therapeutics Inc [NASDAQ: FATE] plunged -3.57% to $1.08. The stock’s lowest price that day was $1.08, but it reached a high of $1.15 in the same session. During the last five days, there has been a drop of approximately -2.70%. Over the course of the year, Fate Therapeutics Inc shares have dropped approximately -72.16%. Shares of the company reached a 52-week high of $1.9900 on 01/06/25 and a 52-week low of $0.6611 on 04/04/25.
Support And Resistance Levels for Fate Therapeutics Inc (FATE)
According to the 24-hour chart, there is a support level at 1.0540, which, if violated, would cause prices to drop to 1.0279. In the upper region, resistance lies at 1.1321. The next price resistance is at 1.1841. RSI (Relative Strength Index) is 47.40 on the 14-day chart, showing neutral technical sentiment.
Is Fate Therapeutics Inc subject to short interest?
Stocks of Fate Therapeutics Inc saw a sharp steep in short interest on 2025-08-15 dropping by 58727.0 shares to 9.4 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 9.46 million shares. A decline of -0.62% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.3 of the overall float, the days-to-cover ratio (short ratio) decline to 6.3.
Which companies own the most shares of Fate Therapeutics Inc (FATE)?
In terms of Fate Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 3 in the next 12 months, up nearly 167.86% from the previous closing price of $1.12. Analysts anticipate Fate Therapeutics Inc stock to reach 3 by 2025, with the lowest price target being 3. In spite of this, 8 analysts ranked Fate Therapeutics Inc stock as Buy at the end of 2025. On January 06, 2023, Wedbush assigned a price target of “a Neutral” to the stock and downgraded coverage with a $7.
